Literature DB >> 26534745

Expression of TLR2 and TLR4 on peripheral blood monocytes during exacerbation of atopic dermatitis.

Namjil N Tsybikov1, Irina Petrisheva, Elena V Fefelova, Boris I Kuznik, Eli Magen.   

Abstract

BACKGROUND: In atopic dermatitis (AD), monocytes, which accumulate in the inflamed skin, are characterized by a significantly impaired Toll-like receptors (TLR) expression and TLR2-mediated cytokine secretion. However, data on expression of TLR on monocytes of peripheral blood (PB) in AD are not available.
OBJECTIVE: To investigate TLR2 and TLR4 expression on PB monocytes during AD exacerbation and to assess the relationships between TLR expressions with AD clinical severity and with serum interleukin (IL) 4, IL-10, and IL-17a levels.
METHODS: The objective Scoring Atopic Dermatitis index, TLR2 and TLR4 expression on CD14(+) human leukocyte antigen-DR (HLA-DR(+)) PB monocytes by flow cytometry, serum IL-4, IL-10, IL-17a (enzyme-linked immunosorbent assay) and total immunoglobulin E levels were measured at study entry and after 4 months in patients with AD and healthy controls.
RESULTS: Eighty-two patients with AD, 35 women (45.1%) and 47 men (54.9%), mean (standard deviation [SD]) age, 42.2 ± 11.5 years, were included. Thirty healthy volunteers served as controls. We observed a significant difference in the levels of TLR2 expression in the CD14(+) HLA-DR(+) PB monocytes of patients with AD (mean [SD], 51.6 ± 23.1% and 264 ± 118 cells/mm(3)) at exacerbation (but not at the end of the 4-month postexacerbation period) compared with the healthy control subjects (mean [SD], 22.3 ± 10.6% and 105 ± 50 cells/mm(3); p < 0.001). TLR4 expression in PB monocytes was significantly greater in AD (mean [SD], 50.1 ± 20.9% and 275 ± 114 cells/mm(3)) than in the healthy subjects (mean [SD], 31.2 ± 8.7% and 147 ± 41 cells/mm(3); p < 0.001) both at exacerbation and at the 4-month postexacerbation period. Significant correlations between TLR2(+) (but not TLR4(+)) PB monocytes and the objective Scoring Atopic Dermatitis index (r = 0.604, p < 0.001), serum levels of IL-17a and TLR2(+) PB monocytes (r = 0.416, p = 0.027), and IL-4 and TLR2(+) PB monocytes (r = -0.307, p = 0.014) were observed during AD exacerbation.
CONCLUSION: PB CD14(+) HLA-DR(+) TLR2(+) monocytes might have a role in the skewing of a T-helper 2/T-helper 17-mediated immune response during AD flare.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26534745     DOI: 10.2500/aap.2015.36.3901

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  5 in total

1.  Asthma, allergy, and psychiatric disease.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2015 Nov-Dec       Impact factor: 2.587

2.  TLR4 polymorphisms as potential predictors of atopic dermatitis in Chinese Han children.

Authors:  Jianrong Shi; Lin He; Ran Tao; Huiwen Zheng; Wei Li; Shuangshuang Huang; Yunling Li; Shiqiang Shang
Journal:  J Clin Lab Anal       Date:  2022-03-29       Impact factor: 3.124

Review 3.  Eosinophilic Esophagitis and Microbiota: State of the Art.

Authors:  Maurizio Mennini; Renato Tambucci; Carla Riccardi; Francesca Rea; Paola De Angelis; Alessandro Fiocchi; Amal Assa'ad
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

4.  Toll-like receptors-mediated pathways activate inflammatory responses in the esophageal mucosa of adult eosinophilic esophagitis.

Authors:  Ángel Arias; María Vicario; David Bernardo; José M Olalla; Marina Fortea; Ana Montalban-Arques; Pilar Martínez-Fernández; Ana M González-Castro; Teresa Mota-Huertas; Laura Arias-González; Alfredo J Lucendo
Journal:  Clin Transl Gastroenterol       Date:  2018-04-25       Impact factor: 4.488

5.  Enhancement of Chemokine mRNA Expression by Toll-Like Receptor 2 Stimulation in Human Peripheral Blood Mononuclear Cells of Patients with Atopic Dermatitis.

Authors:  Yangyang Yu; Dongxu Lin; Xiaoqiong Cai; Danni Cui; Ran Fang; Wei Zhang; Bo Yu; Xiaomei Wang
Journal:  Biomed Res Int       Date:  2020-03-19       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.